Literature DB >> 20104257

Analgesic Response to Morphine in Children with Sickle Cell Disease: A Pilot Study.

Eufemia Jacob1, Marilyn Hockenberry, Brigitta U Mueller, Thomas D Coates, Lonnie Zeltzer.   

Abstract

Morphine given by Patient Controlled Analgesia (PCA) is widely used in hospital settings to manage severe pain during acute painful episodes. Wide variations in prescription patterns occur and some patients are often self-administering sub- or low- therapeutic doses. In this preliminary study, a descriptive design with repeated measures was used to examine the effects of different PCA morphine regimens on the intensity, location and quality of pain as well as on the perceived amount of relief and side effects in patients with sickle cell disease (N=13; mean age 13.7 years; eight males; five females). The preliminary data showed that a regimen with a high background infusion rate and low intermittent push dose (Regimen B) may provide better response to PCA morphine. The difference in trends between the worst and least pain intensity ratings were narrower in this regimen, suggesting that pain peaks and troughs were not occurring as in a regimen with an around the clock nurse administered dosing schedule (Regimen C). The amount of morphine that was administered per day was not significantly different (p > 0.05) among the three morphine regimens. The combination of a high background infusion rate and low intermittent push dose (as in Regimen B) within the first 24 hours of admission, may provide improved response and possibly shorter recovery from the painful episode than the regimen that would routinely be prescribed with lower background infusion rate and high intermittent push dose (as in regimen A).

Entities:  

Year:  2008        PMID: 20104257      PMCID: PMC2810969     

Source DB:  PubMed          Journal:  J Pain Manag        ISSN: 1939-5914


  22 in total

1.  Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool.

Authors:  Linda S Franck; Marsha Treadwell; Eufemia Jacob; Elliott Vichinsky
Journal:  J Pain Symptom Manage       Date:  2002-02       Impact factor: 3.612

2.  Management of vaso-occlusive pain in children with sickle cell disease.

Authors:  Eufemia Jacob; Christine Miaskowski; Marilyn Savedra; Judith E Beyer; Marsha Treadwell; Lori Styles
Journal:  J Pediatr Hematol Oncol       Date:  2003-04       Impact factor: 1.289

3.  Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease.

Authors:  Eufemia Jacob; Christine Miaskowski; Marilyn Savedra; Judith E Beyer; Marsha Treadwell; Lori Styles
Journal:  Pain       Date:  2003-03       Impact factor: 6.961

4.  Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain.

Authors:  A Ruggiero; G Barone; L Liotti; A Chiaretti; I Lazzareschi; R Riccardi
Journal:  Support Care Cancer       Date:  2006-12-05       Impact factor: 3.603

5.  A descriptive study of heavy emergency department users at an academic emergency department reveals heavy ED users have better access to care than average users.

Authors:  Fidela S J Blank; Haiping Li; Philip L Henneman; Howard A Smithline; John S Santoro; Deborah Provost; Ann M Maynard
Journal:  J Emerg Nurs       Date:  2005-04       Impact factor: 1.836

6.  A chronology of pain and comfort in children with sickle cell disease.

Authors:  J E Beyer; L E Simmons; G M Woods; P M Woods
Journal:  Arch Pediatr Adolesc Med       Date:  1999-09

7.  Pain intensity and home pain management of children with sickle cell disease.

Authors:  R L Conner-Warren
Journal:  Issues Compr Pediatr Nurs       Date:  1996 Jul-Sep

8.  Measuring pain quality: validity and reliability of children's and adolescents' pain language.

Authors:  Diana J Wilkie; William L Holzemer; Mary D Tesler; Judith Ann Ward; Steven M Paul; Marilyn C Savedra
Journal:  Pain       Date:  1990-05       Impact factor: 6.961

9.  Impact of an emergency department pain management protocol on the pattern of visits by patients with sickle cell disease.

Authors:  Melissa Givens; Cynthia Rutherford; Girish Joshi; Kathleen Delaney
Journal:  J Emerg Med       Date:  2007-02-07       Impact factor: 1.484

10.  Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients.

Authors:  Y M Yang; A K Shah; M Watson; V N Mankad
Journal:  Public Health Rep       Date:  1995 Jan-Feb       Impact factor: 2.792

View more
  4 in total

1.  Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes.

Authors:  Carlton D Dampier; Wally R Smith; Hae-Young Kim; Carrie Greene Wager; Margaret C Bell; Caterina P Minniti; Jeffrey Keefer; Lewis Hsu; Lakshmanan Krishnamurti; A Kyle Mack; Donna McClish; Sonja M McKinlay; Scott T Miller; Ifeyinwa Osunkwo; Phillip Seaman; Marilyn J Telen; Debra L Weiner
Journal:  Am J Hematol       Date:  2011-09-22       Impact factor: 10.047

2.  Usability testing of a Smartphone for accessing a web-based e-diary for self-monitoring of pain and symptoms in sickle cell disease.

Authors:  Eufemia Jacob; Jennifer Stinson; Joana Duran; Ankur Gupta; Mario Gerla; Mary Ann Lewis; Lonnie Zeltzer
Journal:  J Pediatr Hematol Oncol       Date:  2012-07       Impact factor: 1.289

3.  Remote monitoring of pain and symptoms using wireless technology in children and adolescents with sickle cell disease.

Authors:  Eufemia Jacob; Joana Duran; Jennifer Stinson; Mary Ann Lewis; Lonnie Zeltzer
Journal:  J Am Assoc Nurse Pract       Date:  2012-07-12       Impact factor: 1.165

4.  IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Authors:  Carlton D Dampier; Wally R Smith; Carrie G Wager; Hae-Young Kim; Margaret C Bell; Scott T Miller; Debra L Weiner; Caterina P Minniti; Lakshmanan Krishnamurti; Kenneth I Ataga; James R Eckman; Lewis L Hsu; Donna McClish; Sonja M McKinlay; Robert Molokie; Ifeyinwa Osunkwo; Kim Smith-Whitley; Marilyn J Telen
Journal:  Clin Trials       Date:  2013-04       Impact factor: 2.486

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.